Holders — by stockHoldings — by fund
Velan Capital Investment Management LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001848809
$164.2M
disclosed book value
50
positions
18.1%
largest position share
Positions, as of 2026-06-30
top 51 of 50 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | PRAXPRAXIS PRECISION MEDICINES I | 88,781 | $29.7M | 18.1% |
| 2 | MPLTMAPLIGHT THERAPEUTICS INC | 492,893 | $17.7M | 10.8% |
| 3 | STROSUTRO BIOPHARMA INC | 512,160 | $17.0M | 10.4% |
| 4 | IMMXIMMIX BIOPHARMA INC | 1.1M | $11.2M | 6.8% |
| 5 | TARAPROTARA THERAPEUTICS INC | 2.8M | $10.9M | 6.6% |
| 6 | ABVXABIVAX SA | 65,630 | $8.7M | 5.3% |
| 7 | TENXTENAX THERAPEUTICS INC | 549,985 | $8.0M | 4.9% |
| 8 | AVRANTERIS TECHNOLOGIES GLOBAL | 700,000 | $6.9M | 4.2% |
| 9 | EDSAEDESA BIOTECH INC | 827,500 | $6.7M | 4.1% |
| 10 | EVMNEVOMMUNE INC | 451,255 | $6.0M | 3.7% |
| 11 | AVTXAVALO THERAPEUTICS INC | 324,452 | $6.0M | 3.7% |
| 12 | XNCRXENCOR INC | 255,000 | $4.1M | 2.5% |
| 13 | RZLTREZOLUTE INC | 750,000 | $3.9M | 2.4% |
| 14 | HRTXHERON THERAPEUTICS INC | 8.8M | $3.7M | 2.3% |
| 15 | VRCAVERRICA PHARMACEUTICALS INC | 471,559 | $2.9M | 1.8% |
| 16 | CCCCC4 THERAPEUTICS INC | 570,000 | $2.7M | 1.6% |
| 17 | EPRXEUPRAXIA PHARMACEUTICALS INC | 352,000 | $2.3M | 1.4% |
| 18 | ADMAADMA BIOLOGICS INC | 250,000 | $2.1M | 1.3% |
| 19 | RNTXREIN THERAPEUTICS INC | 1.7M | $1.8M | 1.1% |
| 20 | LYELLYELL IMMUNOPHARMA INC | 105,000 | $1.5M | 0.9% |
| 21 | NASUS PHARMA LTD | 359,390 | $1.3M | 0.8% |
| 22 | PROFPROFOUND MED CORP | 170,278 | $1.1M | 0.7% |
| 23 | JSPRJASPER THERAPEUTICS INC | 2.7M | $1.1M | 0.7% |
| 24 | TENXTENAX THERAPEUTICS INCCALL | 68,700 | $999,585 | 0.6% |
| 25 | PTGXPROTAGONIST THERAPEUTICS INC | 3,700 | $453,546 | 0.3% |
| 26 | CTMXCYTOMX THERAPEUTICS INC. | 120,000 | $450,000 | 0.3% |
| 27 | NMRANEUMORA THERAPEUTICS INC. | 230,000 | $391,000 | 0.2% |
| 28 | NRIXNURIX THERAPEUTICS INC | 16,000 | $388,160 | 0.2% |
| 29 | OVIDOVID THERAPEUTICS INC | 130,000 | $349,700 | 0.2% |
| 30 | DTILPRECISION BIOSCIENCES INC | 40,000 | $314,400 | 0.2% |
| 31 | MLYSMINERALYS THERAPEUTICS INC | 11,000 | $296,780 | 0.2% |
| 32 | MGNXMACROGENICS INC | 60,000 | $277,200 | 0.2% |
| 33 | CRBPCORBUS PHARMACEUTICALS HLDGS | 26,000 | $243,880 | 0.1% |
| 34 | ARTVARTIVA BIOTHERAPEUTICS INC | 25,000 | $242,500 | 0.1% |
| 35 | REPLREPLIMUNE GROUP INC | 20,000 | $221,400 | 0.1% |
| 36 | SNDXSYNDAX PHARMACEUTICALS INC | 10,000 | $218,600 | 0.1% |
| 37 | IMNMIMMUNOME INC | 10,000 | $211,900 | 0.1% |
| 38 | TECXTECTONIC THERAPEUTIC INC | 6,000 | $206,250 | 0.1% |
| 39 | RCKTROCKET PHARMACEUTICALS INC | 60,000 | $205,200 | 0.1% |
| 40 | KPTIKARYOPHARM THERAPEUTICS INC | 20,000 | $195,400 | 0.1% |
| 41 | ANTXAN2 THERAPEUTICS INC | 40,000 | $193,600 | 0.1% |
| 42 | VRDNVIRIDIAN THERAPEUTICS INC | 10,000 | $183,700 | 0.1% |
| 43 | SCYXSCYNEXIS INC | 40,000 | $162,800 | 0.1% |
| 44 | QNRXQUOIN PHARMACEUTICALS LTD | 32,372 | $156,680 | 0.1% |
| 45 | XLOXILIO THERAPEUTICS INC | 14,285 | $136,850 | 0.1% |
| 46 | NSPRINSPIREMD INC | 148,138 | $103,711 | 0.1% |
| 47 | KLRSKALARIS THERAPEUTICS INC | 25,000 | $101,750 | 0.1% |
| 48 | LRMRLARIMAR THERAPEUTICS INC | 33,000 | $100,650 | 0.1% |
| 49 | PROQR THRAPEUTICS N V | 45,000 | $83,700 | 0.1% |
| 50 | CNTXCONTEXT THERAPEUTICS INC | 59,700 | $33,068 | 0% |
| 51 | GOSSGOSSAMER BIO INC | 70,000 | $11,522 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.